



Europass Curriculum Vitae

Personal information

First name[s] / Surname[s] **ANTONIO PINTO**
Address[es] Department of Hematology, Fondazione 'G. Pascale', IRCCS, Via M. Semmola, 80131, Naples, Italy
Telephone[s] +39 (0)81 5903 1816 / 317
Fax[es] +39 (0)81 5903 833
E-mail a.pinto@istitutotumori.na.it
Nationality Italian
Date of birth April, 8th 1957
Gender Male

Occupational field Oncology-Hematology

Work experience

Dates **March 29, 2017 – to date**

Occupation or position held Head, Department of Hematology and Developmental Therapeutics (CORP-S ASSISTENZIALE E DI RICERCA DI EMATOLOGIA E TERAPIE INNOVATIVE)
Head, Hematology/Oncology and Stem Cell transplantation Unit;
Istituto Nazionale Tumori, Fondazione "Pascale", IRCCS, Naples, Italy

Main activities and responsibilities Clinical & preclinical research activity on hemopoietic malignancies; clinical duties & coordination of clinical activities, including stem cell transplantation; administrative activities & duties related to management of clinical and research activity for the Hematology/Oncology and Stem Cell transplantation Unit and the Department of Department of Hematology and Developmental Therapeutics

Name and address of employer Istituto Nazionale Tumori, Fondazione 'G. Pascale', IRCCS,

Type of business or sector Clinical & research activity – Hematology-Oncology

Dates **March 2010 – March 2017**

Occupation or position held Head, Department of Hematology,
Head, Hematology/Oncology and Stem Cell transplantation Unit;
Istituto Nazionale Tumori, Fondazione "Pascale", IRCCS, Naples, Italy

Main activities and responsibilities Clinical & preclinical research activity on hemopoietic malignancies; clinical duties & coordination of clinical activities, including stem cell transplantation; administrative activities & duties related to management of clinical and research activity for the Hematology/Oncology and Stem Cell transplantation Unit and the Department of Hematology.

Name and address of employer Istituto Nazionale Tumori, Fondazione 'G. Pascale', IRCCS,

Type of business or sector Clinical & research activity – Hematology-Oncology

Dates **November 2000 – to date**

Occupation or position held Head, Hematology/Oncology and Stem Cell transplantation Unit;
Istituto Nazionale Tumori, Fondazione "Pascale", IRCCS, Naples, Italy

Main activities and responsibilities	Clinical & preclinical research activity on hemopoietic malignancies; clinical duties & coordination of clinical activities, including stem cell transplantation; administrative activities & duties related to management of clinical and research activity for the Hematology/Oncology and Stem Cell transplantation Unit and the Department of Hematology.
Name and address of employer	Istituto Nazionale Tumori, Fondazione 'G. Pascale', IRCCS,
Type of business or sector	Clinical & research activity - Hematology-Oncology
Dates	1997 to November 2000
Occupation or position held	<i>Head</i> , Developmental Oncology/Hematology and Leukemia Unit; Department of Medical Oncology and Hematology
Main activities and responsibilities	Clinical & preclinical research activity on hemopoietic malignancies; clinical duties & coordination of clinical activities, including stem cell transplantation; administrative activities & duties related to functioning of the Developmental Oncology/Hematology and Leukemia Unit,
Name and address of employer	Centro di Riferimento Oncologico, IRCCS, Aviano, Italy.
Type of business or sector	Clinical & research activity - Hematology-Oncology
Dates	1992 - 1997
Occupation or position held	<i>Associate Director</i> , Division of Medical Oncology; Head, the Leukemia Unit and Bone Marrow Transplantation; Department of Medical Oncology and Hematology
Main activities and responsibilities	Clinical & preclinical research activity on hemopoietic malignancies; clinical duties & coordination of clinical activities, including stem cell transplantation; administrative activities & duties related to functioning of the Leukemia Unit and Bone Marrow Transplantation
Name and address of employer	Centro di Riferimento Oncologico, IRCCS, Aviano, Italy.
Type of business or sector	Clinical & research activity - Hematology-Oncology
Dates	1990 -1992
Occupation or position held	<i>Associate Director</i> , the Leukemia Unit, Division of Experimental Oncology 2
Main activities and responsibilities	Clinical & preclinical research activity on hemopoietic malignancies; clinical duties & coordination of clinical activities including haematological diagnostics [morphology, flow cytometry, molecular biology].
Name and address of employer	Centro di Riferimento Oncologico, IRCCS, Aviano, Italy.
Type of business or sector	Clinical & research activity - Hematology-Oncology
Dates	1986 - 1990
Occupation or position held	<i>Assistant Director</i> , the Leukemia Unit, Division of Experimental Oncology 2
Main activities and responsibilities	Clinical & preclinical research activity on hemopoietic malignancies; clinical duties & coordination of clinical activities including haematological diagnostics [morphology, flow cytometry, molecular biology].
Name and address of employer	Centro di Riferimento Oncologico, IRCCS, Aviano, Italy. Via Pedemontana Occ.le 33081, Aviano [PN] Italy
Type of business or sector	Clinical & research activity - Hematology-Oncology
Education and training	
Dates	1987
Title of qualification awarded	Specialty Board Certificate in HEMATOLOGY Summa cum Laude
Name and type of organisation providing education and training	University of Bari Medical School, Italy
Dates	1984
Title of qualification awarded	Specialty Board Certificate in ONCOLOGY Summa cum Laude
Name and type of organisation providing education and training	Catholic University [Università Cattolica del Sacro Cuore], Rome, Italy
Dates	1981
Title of qualification awarded	Medical Degree [MD] Summa cum Laude [Medicine and Surgery]

Name and type of organisation providing education and training University of Naples, II Medical School, Italy

Education, training and activity at International Medical Institutions

Dates **2000**

Title of qualification awarded Visiting Scientist

Principal subjects/occupational skills covered Development of dendritic cell therapy for patients with hemopoietic tumors; studies on the pathobiology of Hodgkin Lymphoma

Name and type of organisation providing education and training Department of Oncology, Tumor vaccines laboratory, Austin Medical Center, The Ludwig Institute for Cancer Research, Heidelberg, Melbourne, Australia

Dates **1991**

Title of qualification awarded Visiting Scientist

Principal subjects/occupational skills covered Studies on preclinical and clinical development of cAMP analogues as innovative agents for treatment of acute leukemias.

Name and type of organisation providing education and training Laboratory of Tumor Immunology and Biology; NCI/NHI, Bethesda MD, USA

Dates **1986, 1987**

Title of qualification awarded Visiting Fellow

Principal subjects/occupational skills covered Clinical activity on patients with different types of hemopoietic tumors; laboratory diagnosis of hematologic malignancies; preclinical research activity on the biology of B-cell tumors

Name and type of organisation providing education and training Division of Haematology, St. Thomas's Hospital, UMDS of Guy's and St. Thomas's Hospital, University of London

Dates **1985**

Title of qualification awarded Specialist Laboratory Course on "Immunocytochemistry for light microscopy"

Principal subjects/occupational skills covered Laboratory skills and techniques in immunocytochemistry as applied to diagnosis of haematological malignancies and tumor biology

Name and type of organisation providing education and training Royal Postgraduate Medical School, Hammersmith Hospital, University of London.

Dates **1981**

Title of qualification awarded Visiting Fellow

Principal subjects/occupational skills covered Clinical activity, diagnosis and treatment of hemopoietic malignancies, management of severely immunocompromised patients, administration of chemotherapy and management of associated toxicity

Name and type of organisation providing education and training Department of Oncology, Gartnavel Hospital, University of Glasgow, Glasgow

Dates **1979**

Title of qualification awarded Visiting Fellow

Principal subjects/occupational skills covered Clinical training, diagnosis and management of Hodgkin and non-Hodgkin lymphomas; training rotations in medical oncology, surgical oncology and emergency room

Name and type of organisation providing education and training Surgical Oncology Unit, Department of Oncology, Northwick Park Hospital and Clinical Research Centre, London.

Major Areas of Scientific Activity

Design and coordination of phase I-II trials on newer upfront and salvage regimes for Hodgkin's and non-Hodgkin lymphoma and GCP phase III studies with upfront experimental regimes in Hodgkin and non-Hodgkin lymphomas and multiple myeloma.

Development of novel high-dose chemotherapy regimens for Stem Cell Transplantation

Development of novel approaches for Radioimmunotherapy in lymphomas.

Development and validation of novel serum biomarkers for prognostication, risk stratification and clinical monitoring in lymphoma, myeloma and lymphoproliferative disorders

Preclinical studies on activity and patterns of resistance of lymphoma and myeloma cells to novel agents.

Studies on the relevance of cell contact-dependent and cytokine-mediated interactions between Reed-Sternberg cells and reactive cell populations in tissues involved by Hodgkin's disease.

Clinical development for Europe of the DNA-methyltransferases inhibitor 5-aza-2'-deoxycytidine [Decitabine] by design and conduction of phase I and II trials in leukemia and myelodysplastic syndromes.

Preclinical and clinical development of novel target-based agents for patients with refractory and relapsed lymphoma and myeloma.

Advisory Boards

Member of Advisory Boards for novel agents development and definition of optimal clinical practice pathways in lymphomas, myeloma and myelodysplastic syndromes.

Name and type of organisation[s]

Regional Health Authority [Regione Campania] – Institutional, non-profit

Pharmaceutical R & D: Celgene, Gilead, Helssin Healthcare, Mundipharma Int.I, Roche, Spectrum, Takeda, Teva - Profit

Chief Scientific Advisor for the Associazione Volontari Ematologia Pascale [AVEPonlus] – Institutional, non-profit patient-based support organization [fund-raising, home care programs for patients with hemopoietic malignancies, family support, psycho-social interventions]

Academic & Professional Comitees/Working Parties

2013 to date

Member of the Steering Committee of The Fondazione Italiana Linfomi [FIL]

National Coordinator of Hodgkin Lymphoma studies for The Fondazione Italiana Linfomi [FIL]

Member of the International Immuno-Oncology Network (II-ON)

Member of the Campania Society for Oncology Immunotherapy (SCITO)

Member of the Italian Society of Psycho-oncology (SIPO) and of regional Steering Committee

2009-2010

Member of the Regional Committee [Regione Campania] for the definition of reimbursent tracks for high-cost anticancer agents.

2004-2005

Member of the Working Party for the evaluation of non conventional cancer treatments [MDB], Consiglio Superiore di Sanità, National Ministry of Health, Rome, Italy.

2002-2005

Member of the National Committee for Evaluation of Phase I Clinical Trials [Commissione Ministeriale per l' 'accertamento dei requisiti dei prodotti farmaceutici di nuova istituzione, ex art.7 D.P.R. 439/2001], National Ministry of Health, Rome, Italy

2000-2006

Member of the international working group [IWG] for definition of response criteria in myelodysplasia.

Educational Publications, Books and videos for Patients and their Families

2015

Professional Press Release & Academic Video Interviews

1. De Benedetta G, D'Ovidio S, Pinto A. *Mamma Uovo. La malattia spiegata a mio figlio.* Illustrazioni di di Sergio Staino. ISBN : 9788897883517, Marotta & Cafiero Editori, Napoli, 2015
2. De Benedetta G, D'Ovidio S, Pinto A. *Linfoma si può dire ? Come dialogare con i figli sulla propria malattia.* Collana informativa «Conoscere per Combattere», n°4, Fondazione Italiana Linfomi, Lymphoma Coalition, Worldwide Network of Lymphoma Patient Groups, LinfoVita Edizioni, 2015
3. De Benedetta G, D'Ovidio S, Pinto A. *Guida Galattica per gli Esploratori Del Pianeta Linfoma Pensieri ed Emozioni da Esplorare.* Collana informativa «Conoscere per Combattere», n° 9, Fondazione Italiana Linfomi, Lymphoma Coalition, Worldwide Network of Lymphoma Patient Groups, LinfoVita Edizioni, 2015

2013

1. De Benedetta G, D'Ovidio S, Becchimanzi C, Marcacci G, Pinto A. *SI TORNA A CASA Guida alla dimissione dopo il trapianto autologo di cellule staminali* Edizione IRCCS Pascale

2016

Le nuove strategie di salvataggio per il linfoma di Hodgkin
[\[http://www.pharmastar.it/index.html?pgnav=12&id=3244\]](http://www.pharmastar.it/index.html?pgnav=12&id=3244)

2015

Linfoma follicolare recidivato, quanto siamo vicini a una terapia chemio-free?
[\[http://www.pharmastar.it/apple/html/archivionewsletter_viewnl.html?id=2014374733R\]](http://www.pharmastar.it/apple/html/archivionewsletter_viewnl.html?id=2014374733R)

Cosa sono i linfomi

[\[http://www.benessere.com/tv/salute/288_cosa_sono_i_linfomi_quali_terapie_per_il_linfoma_di_hodgkin_e_il_ruolo_dell%2%80%99innovazione_tecnologica.htm\]](http://www.benessere.com/tv/salute/288_cosa_sono_i_linfomi_quali_terapie_per_il_linfoma_di_hodgkin_e_il_ruolo_dell%2%80%99innovazione_tecnologica.htm)

Ematologia di precisione: come funziona, vantaggi

Hodgkin's lymphoma: smart drugs for non-responders [\[http://www.youmed.it/video.do?id=2249\]](http://www.youmed.it/video.do?id=2249)

Linfoma di Hodgkin: la rivoluzione delle cure negli ultimi anni

[\[http://www.pharmastar.it/index.html?pgnav=12&id=2400\]](http://www.pharmastar.it/index.html?pgnav=12&id=2400)

2011

Blood cancer in the elderly European expert forum [\[http://ecancer.org/video/842/blood-cancer-in-the-elderly-european-expert-forum\]](http://ecancer.org/video/842/blood-cancer-in-the-elderly-european-expert-forum)

Burkitt's lymphoma in the elderly [\[http://ecancer.org/video/827/burkitt---s-lymphoma-in-the-elderly.php\]](http://ecancer.org/video/827/burkitt---s-lymphoma-in-the-elderly.php)

Treatment of myelodysplastic syndrome: Expert Roundtable [\[http://ecancer.org/video/901/treatment-of-myelodysplastic-syndrome--expert-roundtable.php\]](http://ecancer.org/video/901/treatment-of-myelodysplastic-syndrome--expert-roundtable.php)

BCEEEF 2011: Treatment of elderly MDS patients.

Other language[s]

Self-assessment

European level [*]

Language

Language

English

Understanding		Speaking		Writing
Listening	Reading	Spoken interaction	Spoken production	
C2	C2	C2	C2	C2

[*] Common European Framework of Reference for Languages

Social skills and competences


Events organization; establishment of patient-based foundations

Organisational skills and competences

1) Independent research activity [1981-1990], 2) Direction of research groups [1990 to date]; 3) Direction of clinical & research Complex Units [1990 to date]; 4) Direction of Departments [2010 to date]; 5) Fund raising [1990 to date];

Technical skills and competences	1) Design and conduction of Phase 1-2, Phase 2 and Phase 3 clinical trials; 2) Independent pre-clinical research [tumor cell biology, molecular biology, biomarkers studies]
Computer skills and competences	Window Packages, GraphPad Prism analysis Softwares, SPSS packages
Artistic skills and competences	Music (opera, rock, folk music)
Other skills and competences	Modern History, WWII aircrafts
Driving licence	Yes
Additional information	Include here any other information that may be relevant, for example contact persons, references, etc. [Remove heading if not relevant, see instructions]
Annexes	1. List of publications on International Journals, including IF [1981-2024]

Naples, June 27, 2024



Antonio Pinto, MD

Annex 1 - Scientific Publications

1. Fusco A., **Pinto A.**, Ambesi-Impiombato F.S., Vecchio G., Tsuchida N. Transformation of rat thyroid epithelial cells by Kirsten murine sarcoma virus. *Int. J. Cancer*, 28: 655-662, 1981. [I.F. 3.283]
2. Fusco A., **Pinto A.**, Tramontano D., Tajana F.G., Vecchio G., Tsuchida N. Block in the expression of differentiation markers of rat thyroid epithelial cells by transformation with Kirsten murine sarcoma virus. *Cancer Res.*, 42: 618-626, 1982. [I.F. 8.370]
3. Colletta G., **Pinto A.**, Di Fiore P.P., Fusco A., Ferrentino M., Avvedimento V.E., Tsuchida N., Vecchio G. Dissociation between transformed and differentiated phenotype in rat thyroid epithelial cells after transformation with a temperature-sensitive mutant of the Kirsten murine sarcoma virus. *Mol. Cell Biol.*, 3: 2099-2109, 1983. [I.F. 9.571]
4. Ferrentino M., Di Fiore P.P., Fusco A., Colletta G., **Pinto A.**, Vecchio G. Expression of the oncogene of the Kirsten murine sarcoma virus in differentiated and undifferentiated rat thyroid epithelial cell lines. *J. Gen. Virol.*, 65: 1955-1961, 1984. [I.F. 2.645]
5. Di Fiore P.P., Grieco M., **Pinto A.**, Attadia V., Porcelli M., Cacciapuoti G., Carteni-Farina M. Inhibition of dimethylsulphoxide induced differentiation of Friend erythroleukemic cells by 5'-methylthioadenosine. *Cancer Res.*, 44: 4096-4103, 1984. [I.F. 8.370]
6. **Pinto A.**, Attadia V., Fusco A., Ferrara F., Spada O.A., Di Fiore P.P. 5-aza-2'-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. *Blood*, 64: 922-927, 1984. [I.F. 8.372]
7. **Pinto A.**, Maio M., Attadia V., Zappacosta S., Cimino R. Modulation of HLA-DR antigens expression in human acute leukemia cells by cytosine arabinoside and 5-aza-2'-deoxycytidine. *Lancet*, ii: 867-868, 1984. [I.F. 11.793]
8. **Pinto A.**, Attadia V. Leukemia therapy by differentiation inducers: the therapeutic concept of differentiation. *The Cancer Journal*, 1: 54, 1986. [I.F. 0.902]
9. Fontana S., Del Vecchio L., Racioppi L., Carbone A., **Pinto A.**, Colletta G., Zappacosta S. Expression and major histocompatibility complex class I antigens in normal and transformed rat thyroid epithelial cell lines. *Cancer Res.*, 47: 4178-4183, 1987. [I.F. 8.370]

10. **Pinto A.**, Colletta G., Del Vecchio L., Rosati R., Attadia V., Cimino R., Colombatti A. C-fos oncogene expression in human hematopoietic malignancies is restricted to acute leukemias with monocytic phenotype and to subsets of B cell leukemias. *Blood*, 70: 1450-1457, 1987. [I.F. 8.372]
11. Fusco A., Portella G., Grieco M., Tajana G., Di Minno G., Polli N., **Pinto A.** A retrovirus carrying the polyomavirus middle T gene induces acute thrombocythemic myeloproliferative disease in mice. *J. Virol.*, 62: 361-365, 1988. [I.F. 5.828]
12. **Pinto A.**, Attadia V., Rosati R., Colletta G., Cimino R., Colombatti A. Differentiation of human leukemic cell lines and fresh leukemia cells by low dose Ara-c: monitoring by expression of C-MYC and C-FOS oncogenes. *Med. Oncol. & Tumor Pharmacother.*, 5: 91-97, 1988. [I.F. 0.636]
13. **Pinto A.**, Del Vecchio L. Expression of myelomonocytic antigens on chronic lymphocytic leukemia cells. *Blood*, 72: 1438, 1988. [I.F. 8.372]
14. Maio M., Tessitori G., **Pinto A.**, Temponi M., Colombatti A., Ferrone S. Differential role of distinct determinants of intercellular adhesion molecule-1 in immunological phenomena. *J. Immunol.*, 143: 181-188, 1989. [I.F. 7.166]
15. Berti E., Cattoretti G., Domenico D., Polli N., Parravicini C., **Pinto A.**, Soligo D. 4th International Workshop on human leucocyte differentiation antigens, Vienna, February 21-25, 1989: a report. *Haematologica*, 7: 401-407, 1989. [I.F. 1.876]
16. Carbone A., Gloghini A., **Pinto A.**, Attadia V., Zagonel V., Volpe R. Monocytoid B-cell lymphoma with bone marrow and peripheral blood involvement at presentation. *Am. J. Clin. Pathol.*, 92: 228-236, 1989. [I.F. 2.635]
17. Marotta G., Sorio R., Gattei V., Bullian P.L., De Rosa L., Mancardi S., Attadia V., Carbone A., Monfardini S., Zagonel V., **Pinto A.** High frequency of cross-lineage antigenic expression in acute myeloid leukemia cells of elderly patients. *Bone Marrow Transplant.*, 4: 20, 1989. [I.F. 2.111]
18. **Pinto A.**, Zagonel V., Attadia V., Bullian P.L., Gattei V., Carbone A., Monfardini S., Colombatti A. 5-aza-2'-deoxycytidine as a differentiation inducer in acute myeloid leukemias and myelodysplastic syndromes of the elderly. *Bone Marrow Transplant.*, 4: 28-32, 1989. [I.F. 2.111]

19. Gattei V., Carbone A., Marotta G., De Rosa L., Mancardi S., Alosi M., Attadia V., Zagonel V., **Pinto A.** Expression of natural killer [NK] antigens in malignant histiocytosis and a subset of acute myelomonocytic leukemias. *Bone Marrow Transplant.*, 4: 22, 1989. [I.F. 2.111]
20. Carbone A., **Pinto A.**, Gloghini A., De Re V., Alosi M., Zagonel V., Tirelli U., Attadia V., Boiocchi M., Volpe R. Report of an unusual small lymphocytic B-cell lymphoma selectively involving the B-zone of lymph node. *Cancer*, 66: 302-312, 1990. [I.F. 3.660]
21. **Pinto A.**, Zagonel V., Carbone A. Bone marrow involvement in cutaneous T-cell lymphoma. *Am. J. Clin. Pathol.*, 94: 119-120, 1990. [I.F. 2.635]
22. Zagonel V., **Pinto A.**, Carbone A. Monocytoid B-cell lymphoma with bone marrow and peripheral blood involvement at presentation. *Am. J. Clin. Pathol.*, 94: 117-118, 1990. [I.F. 2.635]
23. Maio M., **Pinto A.**, Carbone A., Zagonel V., Gloghini A., Marotta G., Cirillo M., Colombatti A., Ferrara F., Del Vecchio L., Ferrone S. Differential expression of CD54/Intercellular Adhesion Molecule-1 in myeloid leukemias and in lymphoproliferative disorders. *Blood*, 76: 783-790, 1990. [I.F. 8.372]
24. **Pinto A.**, Gattei V. The transforming growth factor-beta in the regulation of normal and leukemic myelopoiesis. *Biotherapy*, 2: 385-398, 1990. [I.F. 0.561]
25. Gattei V., Carbone A., Zagonel V., **Pinto A.** Expression of natural killer antigens in a subset of "non-T, non-B" lymphoma/leukaemia with histiocytic features". *Br. J. Haematol.*, 76: 444-446, 1990. [I.F. 3.209]
26. **Pinto A.**, Del Vecchio L., Carbone A., Roncadin M., Volpe R., Serraino D., Monfardini S., Colombatti A., Zagonel V. Expression of myelomonocytic antigens is associated with unfavourable clinico-prognostic factors in B cell chronic lymphocytic leukemia. *Ann Oncol*, 2 : 107-113, 1991. [I.F. 2.867]
27. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. [A. Pinto, Group member actively participating in the study]. Confirmation and improvement of Sokal's prognostic classification of Ph⁺ chronic myeloid leukemia: the value of early evaluation of the course of the disease. *Ann. Hematol.*, 63: 307-314, 1991. [I.F. 1.397]

28. Gattei V., Bernabei P.A., **Pinto A.**, Bezzini R., Ringressi A., Formigli L., Tamini A., Attadia V., Brandi M.L. Phorbol ester induced osteoclast-like differentiation of a novel human leukemic cell line [FLG 29.1]. *J. Cell Biol.*, 116: 437-447, 1992. [I.F. 12.785]
29. **Pinto A.**, Zagonel V., Carbone A., Serraino D., Marotta G., Volpe R., Colombatti A., Del Vecchio L. CD13 expression in B-cell chronic lymphocytic leukemia is associated with the pattern of bone marrow infiltration. *Leuk Lymphoma*, 6: 209-218, 1992. [I.F. 1.099]
30. Carbone A., **Pinto A.**, Gloghini A., Volpe R., Zagonel V. B-zone small lymphocytic lymphoma. A morphologic, immunophenotypic and clinical study with comparison to "well differentiated" lymphocytic disorder. *Human Pathol.*, 23: 438-448, 1992. [I.F. 2.759]
31. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. [A. Pinto, Group member actively participating in the study]. A prospective comparison of α -IFN and conventional chemotherapy in Ph+ Chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. *Haematologica*, 77: 204-214, 1992. [I.F. 1.876]
32. **Pinto A.**, Zagonel V., Carbone A., Del Vecchio L. Expression of myeloid associated antigens in chronic lymphocytic leukaemia. *Br. J. Haematol.*, 82: 173-175, 1992. [I.F. 3.209]
33. **Pinto A.**, Aldinucci D., Gattei V., Zagonel V., Tortora G., Cho-Chung Y.S. Inhibition of the self-renewal capacity of blast progenitors from acute myeloblastic leukemia patients by site-selective 8-chloro-cyclic adenosine 3', 5' monophosphate [8-cl-cAMP]. *Proc. Natl. Acad. Sci. [USA]*, 89: 8884-8888, 1992. [I.F. 10.244]
34. Carbone A., Gloghini A., Volpe R., Attadia V., Gattei V., Zagonel V., **Pinto A.** Follicular lymphoma of compartmentalized small cleaved center cells and mantle zone lymphocytes: evidences for a common lineage derivation of neoplastic cells. *Am. J. Clin. Pathol.*, 98: 437-448, 1992. [I.F. 2.635]
35. The GIMEMA Group. [A. Pinto, Group member actively participating in the study] Incidence of thrombotic complications in adult patients with lymphoblastic leukemia receiving L-Asparaginase during induction therapy: a retrospective study. *Eur. J. Haematol.*, 49: 63-66, 1992. [I.F. 1.846]
36. Marotta G., Zagonel V., **Pinto A.** Induction of LFA-1/CD11a and ICAM-1/CD54 adhesion molecules on neoplastic B cells during in vivo treatment of chronic lymphocytic leukemia with interferon- α 2. *Blood*, 81: 267-269, 1993. [I.F. 8.372]

37. Tirelli U., **Pinto A.**, Marotta G, Crovato M, Quaia M, De Paoli P, Galligioni E, Santini G. Clinical and immunologic study of 205 patients with Chronic Fatigue Syndrome: a case series from Italy. *Arch. Intern. Med.*, 153: 116-120, 1993. [I.F. 5.385]
38. Zagonel V., Lo Re G., Marotta G., Babare R., Sardeo G., Gattei V., De Angelis V., Carbone A., Monfardini S., **Pinto A.** 5-aza-2'-deoxycytidine [Decitabine]: induces trilineage response in unfavourable myelodysplastic syndromes. *Leukemia*, 7 [SM 1]: 30-35, 1993. [I.F. 3.163]
39. Gattei V., Aldinucci D., Petti M.C., Da Ponte A., Zagonel V., **Pinto A.** In vitro and in vivo effects of 5-aza-2'-deoxycytidine [Decitabine] on clonogenic cells from acute myeloid leukemia patients. *Leukemia*, 7 [SM 1]: 42-48, 1993. [I.F. 3.163]
40. Petti M.C., Mandelli F., Zagonel V., De Gregoris C., Merola M.C., Latagliata R., Gattei V., Fazi P., Monfardini S., **Pinto A.** 5-aza-2'-deoxycytidine [Decitabine] in the treatment of poor prognosis acute myelogenous leukemia patients. Preliminary results. *Leukemia*, 7 [SM 1]: 36-41, 1993. [I.F. 3.163]
41. **Pinto A.**, Zagonel V. 5-aza-2'-deoxycytidine [Decitabine] and 5-Azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. *Leukemia*, 7 [SM 1]: 51-60, 1993. [I.F. 3.163]
42. **Pinto A.**, Carbone A., Gloghini A., Marotta G., Volpe R., Zagonel V. Differential expression of cell adhesion molecules in B-zone small lymphocytic lymphoma and other "well differentiated" lymphocytic disorders. *Cancer*, 72: 894-904, 1993. [I.F. 3.660]
43. Carbone A., Gloghini A., Volpe R., **Pinto A.** KP1 [CD68] positive large cell lymphoma: a histopathologic and immunophenotypic characterization of 12 cases. *Human Pathol.*, 24: 886-896, 1993. [I.F. 2.759]
44. The GIMEMA group [A. Pinto, Group member actively participating in the study]. Evidence of a hypercoagulable state in patients with acute lymphoblastic leukemia treated with low dose of E. coli L-Asparaginase: a GIMEMA study. *Thrombosis and Haemostasis*, 69: 12-15, 1993. [I.F. 3.726]
45. Caraglia M., Tagliaferri P., Correale P., Genua G., **Pinto A.**, Del Vecchio S., Esposito G., Bianco A.R. Cytarabine increases the binding of 125I-Epidermal growth factor and 125I-Transferrin and enhances the in vitro targeting of human tumor cells with anti-growth factor Mabs. *Cancer Immunol. Immunother.*, 37: 150-156, 1993. [I.F. 1.931]

46. Correale P., Tagliaferri P, Camera A., Caraglia M., Del Vecchio L., De Laurentis M, **Pinto A.**, Rotoli B., Bianco A.R. CD10/ Common acute lymphoblastic leukemia-associated antigen and adhesion factor expression is predictive for lymphokine-activated killing sensitivity of adult B-lineage acute lymphoblastic leukemia. *Year Immunol.*, Basel, Karger, Vol. 7, pp 90-95, 1993.
47. Italian Cooperative Study Group on Chronic Myeloid Leukaemia . [A. Pinto, Group member actively participating in the study]. Evaluating survival after allogeneic bone marrow transplant for chronic myeloid leukaemia in chronic phase: a comparison of transplant versus no-transplant in a cohort of 258 patients first seen in Italy between 1984 and 1986. *Br.J. Haematol.*, 85: 292-299, 1993. [I.F. 3.209]
48. De Cicco M., Panarello G., Fantin D., Veronesi A., **Pinto A.**, Zagonel V., Monfardini S., Testa V. Parenteral nutrition in cancer patients receiving chemotherapy: effects on toxicity and nutritional status. *Journal of Parenteral and Enteral Nutrition*, 17: 513-518, 1993. [I.F. 1.861]
49. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. [A. Pinto, Group member actively participating in the study]. Prognostic factors in chronic myeloid leukemia. Relationship with interferon and bone marrow transplantation. *Leuk Lymphoma*, 11 [Suppl. 1]: 67-71, 1993. [I.F. 1.099]
50. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. [A. Pinto, Group member actively participating in the study]. Treatment of Ph-positive chronic myeloid leukemia with α -interferon [Roferon-A]. The Italian Cooperative Study Group experience. *Leuk Lymphoma*, 11 [Suppl. 1]: 153-157, 1993. [I.F. 1.099]
51. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. [A. Pinto, Group member actively participating in the study]. Karyotypic conversion by interferon as preparative treatment for autologous BMT in PH positive CML. *Leuk Lymphoma*, 11 [Suppl. 1]: 277-280, 1993. [I.F. 1.099]
52. **Pinto A.**, Gloghini A., Gattei V., Aldinucci D., Zagonel V., Carbone A. Expression of the c-kit receptor in human lymphomas is restricted to Hodgkin's disease and CD30-positive anaplastic large cell lymphomas. *Blood*, 83: 785-792, 1994. [I.F. 8.372]
53. Caraglia M., **Pinto A.**, Correale P., Zagonel V., Genua G., Leardi A., Pepe S., Bianco A.R., Tagliaferri P. 5-aza-2'-deoxycytidine induces growth inhibition and upregulation of epidermal growth factor receptor on human epithelial cancer cells. *Ann Oncol*, 5: 269-276, 1994. [I.F. 2.867]
54. **Pinto A.**, Gattei V., Soligo D., Parravicini C., Del Vecchio L. New molecules burst at the leukocyte surface. *Leukemia*, 8: 347-358, 1994. [I.F. 3.163]

55. De Paoli P., D'Andrea M., Santini G., Zagonel V., **Pinto A.**, Carbone A. Serum levels of adhesion molecules in haematopoietic tumors. *Immunol Today*, 15: 339, 1994. [I.F. 15.439]
56. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. [A. Pinto, Group member actively participating in the study] Interferon Alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. *N. Engl. J. Med.*, 330: 820-825, 1994. [I.F. 28.660]
57. Tagliaferri P., Caraglia M., Muraro R., **Pinto A.**, Budillon A., Zagonel V., Bianco A.R. Pharmacological modulation of peptide growth factor receptor expression on tumor cells as a basis for cancer therapy. *Anticancer Drugs*, 5: 379-393, 1994. [I.F. 1.320]
58. Roncadin M., Arcicasa M., Zagonel V., Bortolus R., Valeri P., **Pinto A.**, De Paoli A., Franchin G., Carbone A., Trovò M. Total Body Irradiation and Prednimustine in chronic lymphocytic leukemia and low grade non-Hodgkin's lymphomas. A nine-year experience at a single institution. *Cancer*, 74: 978-984, 1994. [I.F. 3.660]
59. Zagonel V., **Pinto A.**, Serraino D., Babare R., Sacco C., Merola M.C., Trovò M., Tirelli U., Monfardini S. Lung cancer in the elderly. *Cancer Treat Rev*, 20: 315-329, 1994. [I.F. 2.250]
60. Carbone A., Cozzi M., Gloghini A., **Pinto A.** CD26/DPPIV expression in human lymphomas is restricted to CD30+ anaplastic large cell and a subset of T-cell non-Hodgkin's lymphomas. *Human Pathol.*, 25: 1360-1365, 1994. [I.F. 2.759]
61. Tirelli U., Marotta G., Improta S., **Pinto A.** Immunological abnormalities in patients with chronic fatigue syndrome. *Scand. J. Immunol.*, 40: 601-608, 1994. [I.F. 1.781]
62. Carbone A., Gloghini A., Gattei V., Aldinucci D., Degan M., De Paoli P., Zagonel V., **Pinto A.** Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. *Blood*, 85: 780-789, 1995. [I.F. 8.372]
63. Carbone A., Gloghini A., Gruss H-J., **Pinto A.** CD40 antigen expression on Reed-Sternberg cells. A reliable diagnostic tool for Hodgkin's disease. *Am. J. Pathol.*, 146: 780-781, 1995. [I.F. 6.043]
64. Manfioletti G., Gattei V., Buratti E., Rustighi A., De Iuliis A., Aldinucci D., Goodwin G.H., **Pinto A.** Differential expression of a novel proline-rich homeobox gene [Prh] in human hemato lymphopoietic cells. *Blood*, 85: 1237-1245, 1995. [I.F. 8.372]

65. Formigli L., Zecchi Orlandini S., Benvenuti S., Masi L., **Pinto A.**, Gattei V., Bernabei P.A., Gehron Robey P., Collin-Osdoby P. Brandi M.L. In vitro structural and functional relationships between preosteoclastic and bone endothelial cells: a juxtacrine model for migration and adhesion of osteoclast precursors. *J. Cell. Physiol.*, 162: 199-212, 1995. [I.F. 2.843]
66. Correale P., Caraglia M., Fabbrocini A., Guarrasi R., Pepe S., Patella V., Marone G., **Pinto A.**, Bianco A.R., Tagliaferri P. Bryostatins 1 enhances lymphokine activated killer [LAK]-sensitivity and modulates $\beta 1$ integrins profile of cultured human tumor cells. *Anticancer drugs*, 6: 285-290, 1995. [I.F. 1.320]
67. Carbone A., Gloghini A., Gruss H-J, **Pinto A.** CD40 ligand is constitutively expressed in a subset of T-cell lymphomas and on the microenvironmental reactive T-cells of follicular lymphomas and Hodgkin's disease. *Am. J. Pathol.*, 147: 912-922, 1995. [I.F. 6.043]
68. Carbone A., Gloghini A., Zagonel V., **Pinto A.** An update on the diagnostic relevance of CD26 antigen expression in CD30 positive anaplastic large cell lymphoma. *Human Pathol.*, 26: 1169-1170, 1995. [I.F. 2.759]
69. Carbone A., Gloghini A., Zagonel V., Aldinucci D., Gattei V., Degan M., Improta S., Sorio R., Monfardini S., **Pinto A.** The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin's lymphoma/leukemias. *Blood*, 86: 4617-4626, 1995. [I.F. 8.372]
70. Falini B., Bigerna B., Pasqualucci L., Fizzotti M., Martelli M.F., Pileri S., **Pinto A.**, Carbone A., Venturi S., Pacini R., Cattoretti G., Pescarmona E., Lo Coco F., Pelicci P.G., Agnastopoulos I., Della-Favera R., Flenghi L. Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease. *Blood*, 87: 456-471, 1996. [I.F. 8.372]
71. Gattei V., Aldinucci D., Quinn M.W.J., Degan M., Cozzi M., Perin V., De Iulii A., Juzbasic S., Improta S., Athanasou N. A., Ashman L.K., **Pinto A.** Human osteoclasts and preosteoclasts cells [FLG 29.1] express functional c-kit receptors and interact with osteoblast and stromal cells via membrane-bound stem cell factor. *Cell Growth and Differentiation*, 7: 753-763, 1996. [I.F. 4.269]
72. Carbone A., Gloghini A., **Pinto A.** CD40: A sensitive marker of Reed-Sternberg Cells. *Blood*, 87: 4918-4919, 1996. [I.F. 8.372]
73. Gruss H-J., **Pinto A.**, Gloghini A., Wehnes E., Wright B., Boiani N., Aldinucci D., Gattei V., Zagonel V., Smith C.A., Kadin M.E., von Schilling C., Goodwin R.G., Herrmann F., Carbone A. CD30 ligand expression in non-malignant and Hodgkin's disease-involved lymphoid tissues. *Am. J. Pathol.*, 149: 469-481, 1996. [I.F. 6.043]

74. Zagonel V., Fratino L., Sacco C., Babare R., Spazzapan S, Gattei V., Improta S., **Pinto A.** Reducing chemotherapy-associated toxicity in elderly cancer patients. *Cancer Treat Rev*, 22: 223-244, 1996. [I.F. 2.250]
75. Tirelli U., Bernardi D., Improta S., **Pinto A.** Immunologic abnormalities in chronic fatigue syndrome. *J J. Chronic Fatigue Syndr.*, 2: 85-96, 1996.
76. Grignani F., Testa U., Rogaia D., Ferrucci P.F., Samoggia P., **Pinto A.**, Aldinucci D., Gelmetti V., Fagioli M., Alcalay M., Seeler J., Grignani F., Nicoletti I., Peschle C., Pelicci P.G. Effects on differentiation by the promyelocytic leukemia PML/RAR α protein depend on the fusion of the PML protein-dimerization and RAR α DNA binding domains. *EMBO Journal*, 15: 4949-4958, 1996. [I.F. 13.171]
77. **Pinto A.**, Aldinucci D., Gloghini A., Zagonel V., Degan M., Improta S., Perin V., Todesco M., Juzbasic S., Gattei V., Herrmann F., Gruss H.-J., Carbone A. Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. *Blood*, 88: 3299-3305, 1996. [I.F. 8.372]
78. **Pinto A.**, Aldinucci D., Gloghini A., Zagonel V., De Iuliis A., Degan M., Improta S., Todesco M., Perin V., Sacco C., Gattei V., Gruss H.-J., Carbone A. The role of eosinophils in the pathobiology of Hodgkin's disease. *Ann Oncol* , 8 [Suppl. 2]: 89-96, 1997. [I.F. 2.867]
79. Gruss H-J, **Pinto A.**, Duyster J., Poppema S., Herrmann F. Hodgkin's disease: a tumor with disturbed immunological pathways. *Immunol. Today*, 18: 156-163, 1997. [I.F. 15.439]
80. Gattei V., Degan M., Gloghini A., De Iuliis A., Improta S, Rossi FM, Aldinucci D, Perin V., Serraino D, Babare R., Zagonel V., Gruss H-J, Carbone A., **Pinto A.** CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. *Blood*, 89: 2048-2059, 1997. [I.F. 8.372]
81. Gattei V., Cerrato A., Celetti A., Degan M., De Iuliis A., Rossi M.F., Chiappetta G., Consales C., Improta S., Zagonel V., Aldinucci D., Agosti V., Santoro M., Vecchio G., **Pinto A.**, Grieco M. Expression of the RET receptor tyrosine kinase and GDNFR- α in normal and leukemic human hematopoietic cells and stromal cells of the bone marrow microenvironment. *Blood*, 89: 2925-2937, 1997. [I.F. 8.372]
82. Gruss H.-J., Hermann F., Gattei V., Gloghini A., **Pinto A.**, Carbone A. CD40/CD40 ligand interactions in normal, reactive and malignant lympho-hematopoietic tissues. *Leuk Lymphoma*, 24: 393-422, 1997. [I.F. 1.099]

83. Carbone A., Gloghini A., Gattei V., Degan M., Improta S., Aldinucci D., Canzonieri V., Perin T., Gaidano G., Zagonel V., **Pinto A.** Reed-Sternberg cells of classical Hodgkin's disease react with the plasma cell-specific monoclonal antibody B-B4 and express human syndecan-1. *Blood*, 89: 3787-3794, 1997. [I.F. 8.372]
84. Gattei V., Aldinucci D., Degan M., De Iuliis A., Rossi M.F., **Pinto A.** Cytokine-receptors repertoire of osteoclast progenitors. *Br. J. Haematol.*, 97: 934-936, 1997. [I.F. 3.209]
85. Caraglia M., Passeggio A., Beninati S., Leardi A., Nicolini L., Improta S., **Pinto A.**, Bianco A.R., Tagliaferri P., Abbruzzese A. Interferon α 2 recombinant and epidermal growth factor modulate proliferation and hypusine synthesis in human epidermoid cancer KB cells. *Biochem J*, 324: 737-741, 1997. [I.F. 3.855]
86. Gattei V., Degan M., De Iuliis A., Rossi F.M., Aldinucci D., **Pinto A.** Competitive reverse transcriptase PCR: a useful alternative to Northern blotting for quantitative estimation of relative abundances of specific mRNAs in precious samples. *Biochem J*, 325: 565-567, 1997. [I.F. 3.855]
87. Zagonel V, Babare R, Spazzapan S, Rupolo M, Bordonaro R, Ferrara F, **Pinto A.** Treatment of multiple myeloma and acute myelogenous leukemia in the elderly: an update. *Rays*, 22 [Suppl. to n. 1]: 30-36, 1997.
88. Attadia V., Alosi M, Improta S, Zagonel V, Martinazzo G, Carbone A., **Pinto A.** Spectrophotometric detection of RT-PCR amplified BCR/ABL fusion transcripts. A survey performed on archival haematological slides. *Am. J. Clin. Pathol.*, 108: 383-390, 1997. [I.F. 2.636]
89. Caraglia M., Leardi A.I., Improta S., Perin V., Ricciardi B., Arra C., Ferraro P., Fabbrocini A., **Pinto A.**, Bianco A.R., Tagliaferri P. Transient exposure to cytarabine increases peptide growth factor receptor expression and tumorigenicity of melanoma cells. *Anticancer Res.*, 17: 2369-2375, 1997. [I.F. 1.236]
90. Gattei V., Aldinucci D., Attadia V., Degan M., Alosi M.S., De Iuliis A., Babare R., Rossi F.M., Rupolo M., Zagonel V., **Pinto A.** Human granulocyte-macrophage colony-stimulating factor supports the clonogenic growth of B-lineage acute lymphoblastic leukemias expressing myeloid antigens. *Cytokines Cell. Mol. Ther.*, 3: 141-151, 1997. [I.F. 0.962]
91. Carbone A., Cilia A.M., Gloghini A., Canzonieri V., Pastore C., Todesco M., Cozzi M., Perin T., Volpe R., **Pinto A.**, Gaidano G. Establishment of HHV-8 positive and HHV-8 negative lymphoma cell lines from primary lymphomatous effusions. *Int. J. Cancer*, 73: 562-569, 1997. [I.F. 3.283]

92. Gaidano G., Gloghini A., Gattei V., Rossi M.F., Cilia A.M., Godeas C., Degan M., Perin T., Canzonieri V., Aldinucci D., Saglio G., Carbone A., **Pinto A.** Association of KSHV positive primary effusion lymphomas with expression of the CD138/syndecan-1 antigen. *Blood*, 90: 4894-4900, 1997. [I.F. 8.372]
93. Zagonel V., Rupolo M., **Pinto A.** Active protection from chemotherapy toxicity. EORTC Guidelines for the Management of Cancer in the Elderly. *Crit Rev Oncol Hematol*, 27: 125-127, 1998. [I.F. 1.868]
94. **Pinto A.**, Zullian G.B., Archimbaud E. Acute myelogenous leukemia. EORTC Guidelines for the Management of Cancer in the Elderly. *Crit Rev Oncol Hematol*, 27: 161-164, 1998. [I.F. 1.868]
95. **Pinto A.**, Gattei V., Zagonel V., Aldinucci D., Degan M., De Iuliis A., Rossi F.M., Tassan Mazzocco F., Godeas C., Rupolo M., Poletto D., Gloghini A., Carbone A., Gruss H-J. Hodgkin's disease: a disorder of dysregulated cellular cross-talk. *Biotherapy*, 10: 309-320, 1998. [I.F. 0.561]
96. Ferrara F., Mirto S., Zagonel V., **Pinto A.** Acute myeloid leukemia in the elderly: a critical review of therapeutic approaches and appraisal of results of therapy. *Leuk Lymphoma*, 29: 375-382, 1998. [I.F. 1.099]
97. Montillo M., Mirto S., Petti M.C., Latagliata R., Magrin S., **Pinto A.**, Zagonel V., Mele G., Tedeschi A., Ferrara F. Fludarabine, Cytarabine and G-CSF [FLAG] for the treatment of poor risk acute myeloid leukemia. *Am. J. Hematol.*, 58: 105-109, 1998. [I.F. 1.483]
98. The Italian Cooperative Study Group on Chronic Myeloid Leukemia [A. Pinto, Group member actively participating in the study] Long term follow-up of the Italian trial of interferon- α versus conventional chemotherapy in chronic myeloid leukemia. *Blood*, 92: 1541-1548, 1998. [I.F. 8.372]
99. Gattei V., Degan M., Aldinucci D., De Iuliis A., Rossi F.M., Tassan-Mazzocco F., Rupolo M., Zagonel V., **Pinto A.** Differential expression of the RET gene in human acute myeloid leukemia. *Ann. Hematol.*, 77: 207-210, 1998. [I.F. 1.397]
100. Gattei V., Godeas C., Degan M., Rossi M.F., Aldinucci D., **Pinto A.** Characterization of anti-CD138 monoclonal antibodies as tools for investigating the molecular polymorphism of Syndecan-1 in human lymphoma cells. *Br. J. Haematol.*, 104: 152-162, 1999. [I.F. 3.209]

101. Gattei V., Degan M., Rossi F.M., De Iuliis A., Tassan Mazzocco F., Cesa E., Aldinucci D., Zagonel V., **Pinto A.** The RET receptor tyrosine kinase, but not its specific ligand, GDNF, is preferentially expressed by acute leukaemias of monocytic phenotype and is up-regulated upon differentiation. *Br. J. Haematol.*, 105: 225-240, 1999. [I.F. 3.209]
102. Ferrara F., Melillo L., Montillo M., Leoni F., **Pinto A.**, Mele G., Mirto S. Fludarabine, Cytarabine and G-CSF [FLAG] for the treatment of acute myeloid leukemia relapsing from autologous stem cell transplantation. *Ann. Hematol.*, 78: 380-384, 1999. [I.F. 1.397]
103. The Italian Cooperative Study Group On Chronic Myeloid Leukemia and Italian Group for Bone Marrow Transplantation [A. Pinto Group member actively participating in the study] Monitoring treatment and survival in chronic myeloid leukemia. *J. Clin. Oncol.*, 17: 1858-1868, 1999. [I.F. 8.228]
104. Gattei V., Degan M., Rossi F.M., De Iuliis A., Tassan Mazzocco F., Serraino D., Zagonel V., Aldinucci D., **Pinto A.** CD30 ligand [CD30L]-expressing acute myeloid leukemias: a new model of paracrine interactions for the regulation of blast cell proliferation. *Leuk Lymphoma*, 35: 21-35, 1999. [I.F. 1.099]
105. Ferrara F., Leoni F., **Pinto A.**, Mirto S., Morra E., Zagonel V., Mele G., Ciolli S., Magrin S., Montillo M. Fludarabine, Cytarabine and G-CSF for the treatment of high risk myelodysplastic syndrome. *Cancer*, 86: 2006-2013, 1999. [I.F. 3.660]
106. The Italian Co-Operative Study Group on Chronic Myeloid Leukemia [A. Pinto Group member actively participating in the study] A prospective study of alpha-interferon and autologous bone marrow transplantation in chronic myeloid leukemia. *Haematologica*, 84: 707-715, 1999. [I.F. 1.876]
107. Horie R., Gattei V., Ito K., Imajo-Ohmi S., Tange T., Miyauchi J., **Pinto A.**, Degan M., De Iuliis A., Tassan Mazzocco F., Rossi F. M., Higashihara M., Watanabe T. Frequent expression of the variant CD30 [CD30v] in human malignant myeloid and lymphoid neoplasms. *Am. J. Pathol.*, 155: 2029-2041, 1999 [I.F. 6.043]
108. Ferrara F., Annunziata M., Copia C., Mirto S., Zagonel V., **Pinto A.** Presentation and management of acute myeloid leukemia in the very elderly patients. *Clinical Geriatrics*, 8: 81-100, 2000.
109. Aldinucci D., Poletto D., Zagonel V., Rupolo M., Degan M., Nanni P., Gattei V., **Pinto A.** In vitro and in vivo effects of 2'-deoxycoformycin [Pentostatin] on tumor cells from human $\gamma\delta$ + T-cell malignancies. *Br. J. Haematol.*, 110: 188-196, 2000. [I.F. 3.209]

110. Degan M., Tassan Mazzocco F., Di Francia R., Rossi F.M., **Pinto A.**, Gattei V. Normalizing complementary DNA by quantitative reverse transcriptase-polymerase chain reaction of $\kappa 2$ -microglobulin: molecular monitoring of minimal residual disease in acute promyelocytic leukemia. *Diagn. Mol. Pathol.*, 9: 98-109, 2000. [I.F. 1.899]
111. Cheson B.D., Bennett J.M., Kantarjian H., **Pinto A.**, Schiffer C.A., Nimer S.D., Löwemberg B., Beran M., de Witte T.M., Stone R.M., Mittelman M., Sanz G.F., Wijermans P.W., Gore S, Greenberg P.L. Report of an International Working Group to standardize response criteria for myelodysplastic syndromes. *Blood*, 96: 3671-3674, 2000. [I.F. 8.372]
112. **Pinto A.**, Zagonel V., Ferrara F. Acute myeloid leukemia in the elderly: biology and therapeutic strategies. *Crit. Rev. Oncol. Hematol.*, 39: 275-87, 2001 [I.F. 1.868]
113. Zagonel V., Monfardini S., Tirelli U., Carbone A., **Pinto A.** Management of hematologic malignancies in the elderly: a 15 years experience at the Aviano Cancer Center. *Crit. Rev. Oncol. Hematol.*, 39: 289-305, 2001. [I.F. 1.868]
114. Rossi F.M., Degan M., Mazzocut-Zecchin L., Di Francia R., Aldinucci D., **Pinto A.**, Gattei V. CD30L up-regulates CD30 and IL-4 expression by T cells. *FEBS Lett.*, 508: 418-22, 2001. [I.F. 3.644]
115. Aldinucci D., Poletto D., Gloghini A., Nanni P., Degan M., Perin T., Ceolin P., Rossi F.M., Gattei V., Carbone A., **Pinto A.** Expression of functional interleukin-3 receptors on Hodgkin and Reed-Sternberg cells. *Am. J. Pathol.*, 160: 585-96, 2002. [I.F. 6.750]
116. Rossi F.M., Degan M., Mazzocco F.T., Di Francia R., Aldinucci D., Poletto D., Vellenga E., **Pinto A.**, Gattei V. Co-expression of CD30 ligand and interleukin 4 [IL-4] receptors by acute myeloid leukaemia blasts is associated with the expansion of IL-4-producing CD30+ normal T cells. *Br. J. Haematol.*, 117: 59-69, 2002. [I.F. 3.052]
117. Aldinucci D., Poletto D., Nanni P., Degan M., Gloghini A., Di Francia R., Russo S., Carbone A., **Pinto A.**, Gattei V. Hodgkin and Reed-Sternberg cells express functional c-kit receptors and interact with primary fibroblasts from Hodgkin's disease-involved lymph nodes through soluble and membrane-bound stem cell factor. *Br. J. Haematol.*, 118: 1055-64, 2002 [I.F. 3.052]
118. Aldinucci D., Poletto D., Nanni P., Degan M., Rupolo M., **Pinto A.**, Gattei V. CD40L induces proliferation, self-renewal, rescue from apoptosis, and production of cytokines by CD40-expressing AML blasts. *Exp. Hematol.*, 30: 1283-1292, 2002 [I.F. 3.336]

119. Sigalotti L, Altomonte M, Colizzi F, Degan M, Rupolo M, Zagonel V, **Pinto A.**, Gattei V., Maio M., Lubbert M., Wijermans P.W., Jones PA, Hellstrom-Lindberg E. 5-Aza-2'-deoxycytidine [decitabine] treatment of hematopoietic malignancies: a multimechanism therapeutic approach ? *Blood*, 101:4644-6, 2003 [I.F. 10.120]
120. **Pinto A.**, De Filippi R., Frigeri F., Corazzelli G., Normanno N. Aging and the hemopoietic system. *Crit. Rev. Oncol. Hematol.*, 48s: S3-S12, 2003 [I.F. 2.979]
121. Aldinucci D., Poletto D., Lorenzon D., Nanni P., Degan M., Olivo K., Rapanà B., **Pinto A.**, Gattei V. CD26 expression correlates with a reduced sensitivity to 2'-deoxycoformycin-induced growth inhibition and apoptosis in T-cell leukemia/lymphomas. *Clin. Cancer Res.*, 10: 508-520, 2004 [I.F. 5.623]
122. Talamini R., Montella M., Crovatto M., Dal Maso L., Crispo A., Negri E., Spina M., **Pinto A.**, Carbone A., Franceschi S. Non-Hodgkin lymphoma and hepatitis B and C viruses: a case control study from northern and southern Italy. *Int. J. Cancer*, 110: 380-385, 2004 [I.F. 4.416]
123. **Pinto A.**, Capobianco G., Della Cioppa P., Corazzelli G. Emerging new drugs in the treatment of lymphoma. *Tumori*, 3: S112-S119, 2004 [I.F. 0.631]
124. Rotoli B., Catalano L., Galderisi M., Luciano L., Pollio G., Guerriero A., D'Errico A., Mecucci C., La Starza R., Frigeri F., Di Francia R., **Pinto A.** Rapid reversion of Loeffler's endocarditis by imatinib in early stage clonal hypereosinophilic syndrome. *Leuk Lymphoma*, 12: 2503-2507, 2004 [I.F. 1.147]
125. Corazzelli G., Capobianco G., Russo F., Frigeri F., Aldinucci D., **Pinto A.** Pentostatin [2'-deoxycoformycin] for the treatment of hepatosplenic $\gamma\delta$ T-cell lymphomas. *Haematologica*, 90:ECR14, 2005. [I.F. 4.575]
126. Aldinucci D., Olivo K., Lorenzon D., Poletto D., Gloghini A., Carbone A, **Pinto A.** The role of interleukin-3 in classical Hodgkin's disease. *Leuk Lymphoma*, 46: 303-11, 2005 [I.F. 1.295]
127. D'Arena G., Gambardella M., Ciccirello S., Parisi E., Crocamo A., Marcacci G., Vigliotti M.L., Della Cioppa P., Pizzolante L., **Pinto A.** Pseudothrombocytopenia during Varicella-Zoster infection *Haema*, 8: 534-536, 2005
128. Normanno N., De Luca A., Aldinucci D., Maiello M.R., Mancino M., D'Antonio A., De Filippi R., **Pinto A.** Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. *Endocr Relat. Cancer*, 12:471-482, 2005. [I.F. 4.905]

129. Montella M., Dal Maso L., Crispo A., Talamini R., Bidoli E., Grimaldi M., Giudice A., **Pinto A.**, Franceschi S. Do childhood diseases affect NHL and HL risk? A case-control study from northern and southern Italy. *Leukemia Res.*, 30: 917-922, 2006. [I.F. 2.483]
130. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, **Pinto A.**, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H. Clinical application and proposal for modification of the international working group [IWG] response criteria in myelodysplasia. *Blood*, 108:419-425, 2006. [I.F. 10.370]
131. D'Arena G., De Filippi R., **Pinto A.** DAT-negative hemolytic anemia in a chronic lymphocytic leukemia patient treated with Alemtuzumab. *Leuk. Lymphoma*, 48: 625-627, 2007. [I.F. 1.512]
132. Russo F, Lastoria S, Svanera G, Capobianco G, de Chiara A, Francia R, Squame E, de Martinis F, **Pinto A.** Long-term follow-up study on the role of serum CA-125 as a prognostic factor in 221 newly diagnosed patients with Hodgkin's lymphoma. *Leuk. Lymphoma*, 48: 723-730, 2007. [I.F. 1.512]
133. Ferrara F, **Pinto A.** Acute myeloid leukemia in the elderly: current therapeutic results and perspectives for clinical research. *Rev Recent Clin Trials*. 2007; 2:33-41.
134. D'Arena G., Tarnani M., Rumi C., Vaisitti T., Aydin S., De Filippi R., Perrone F., **Pinto A.**, Chiusolo P., Deaglio S., Malavasi F., Laurenti L. Prognostic significance of combined significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia *Am. J. Hematol.*, 82:787-91, 2007. [I.F. 1.949]
135. D'Arena G., Califano C., Annunziata M., Tartarone A., Capalbo S., Villani O., Amendola G., Pietrantuono G., Ferrara F., **Pinto A.**, Musto P., D'Arco A.M., Cascavilla N. Rituximab for warm type idiopathic autoimmune hemolytic anemia in adults. *European J. Hematol.*, 79: 53-58, 2007. [I.F. 2.163]
136. Gallamini A., Zaja F., Patti C., Billio A., Specchia M.R., Tucci A., Levis A., Manna A., Secondo V., Rigacci L., **Pinto A.**, Iannitto E., Zoli V., Torchio P.F., Pileri S., Tarella C. Alemtuzumab [Campath-1H] and CHOP chemotherapy as first-line treatment of Peripheral T-cell Lymphoma: results of a GITIL prospective multicenter trial. *Blood*, 110:2316-23, 2007 [I.F. 10.896]
137. De Luca A., Carotenuto A., Rachiglio A., Gallo M., Maiello M.R., Aldinucci D., **Pinto A.**, Normanno N. The role of the EGFR signaling in tumor microenvironment *J. Cell Physiol.*, 214:559-567, 2007 [I.F. 3.643]

138. De Benedetta G, Ruggiero G, **Pinto A**. Parents, children and parenting in cancer patients: a still poorly addressed issue in the global management of neoplastic diseases. *Recenti Prog Med*. 2008; 99: 19-26.
139. San Miguel JF, San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG; VISTA Trial Investigators [**A. Pinto**]. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. *N Engl J Med*. 2008; 359: 906-17 [I.F. 50.17]
140. Aldinucci D, Lorenzon D, Cattaruzza L, **Pinto A**, Gloghini A, Carbone A, Colombatti A. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. *Int J Cancer*. 2008; 122:769-76 [I.F. 4.734]
141. Corazzelli G., Capobianco G., Arcamone M., Ballerini PF, Iannitto E., Russo F., Frigeri F., Becchimanzi C., Marcacci G., De Chiara A., **Pinto A**. Long term results of Gemcitabine plus Oxaliplatin with and without Rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B cell lymphoma. *Cancer Chemother Pharmacol*. 2009; 64:907-916. [I.F. 2.740]
142. Marcacci G., Corazzelli G., Becchimanzi C., Arcamone M., Capobianco G., Russo F., Frigeri F., **Pinto A**. DMSO-associated encephalopathy during autologous peripheral stem cell infusion: a predisposing role of preconditioning exposure to CNS-penetrating agents ? *Bone Marrow Transplant*. 2009; 44:133-135. [I.F. 2.998]
143. Frigeri F., Arcamone M., Luciano L., Di Francia R., Pane F., **Pinto A**. Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome-positive leukemia. *Blood* 2009;113: 5028-5029. [IF 10.555]
144. Cattaruzza L, Gloghini A, Olivo K, Di Francia R, Lorenzon D, De Filippi R, Carbone A, Colombatti A, **Pinto A**, Aldinucci D. Functional coexpression of Interleukin [IL]-7 and its receptor [IL-7R] on Hodgkin and Reed-Sternberg cells: involvement of IL-7 in tumor cell growth and microenvironmental interactions of Hodgkin's lymphoma. *Int J Cancer*. 2009;125:1092-1101 [I.F. 4.734]

145. Ruscitti C, Guadagni S, Russo F, Palumbo G, Fiorentini G, Mambrini A, Cantore M, Kanavos E, **Pinto A**, Amicucci G. Thoracic stop-flow perfusion for refractory lymphoma: a phase I-II evaluation trial. *In Vivo*. 2009;23:447-57 [I.F. 1.143]
146. De Filippi R, Iaccarino G, Frigeri F, Di Francia R, Crisci S, Capobianco G, Arcamone M, Becchimanzi C, Amoroso B, De Chiara A, Corazzelli G, **Pinto A**. Elevation of clonal serum free light chains in patients with HIV-negative primary effusion lymphoma [PEL] and PEL-like lymphoma. *Br J Haematol*. 2009;147:405-8 [I.F. 4.597]
147. Omodei D, Acampora D, Russo F, De Filippi R, Severino V, Di Francia R, Frigeri F, Mancuso P, De Chiara A, **Pinto A**, Casola S, Simeone A. Expression of the brain transcription factor OTX1 occurs in a subset of normal germinal-center B cells and in aggressive Non-Hodgkin Lymphoma. *Am J Pathol*. 2009;175:2609-17.[I.F. 5.673]
148. Corazzelli G, De Filippi R, Capobianco G, Frigeri F, De Rosa V, Iaccarino G, Russo F, Amoroso B, Arcamone M, Becchimanzi C, Crisci S, Marcacci G, Lastoria S, **Pinto A**. Tumor flare reactions and response to lenalidomide in patients with refractory Hodgkin Lymphoma. *Am J Hematol*. 2010;85:87-90 [I.F. 2.610]
149. Aldinucci D, **Pinto A**, Gloghini A, Carbone A. Chemokine receptors as therapeutic tools in Hodgkin Lymphoma: CCR4 and beyond. *Blood* 2010;115:746-7 [I.F. 10.555]
150. Musso M, Scalone R, Marcacci G, Lanza F, Di Renzo N, Cascavilla N, Di Bartolomeo P, Crescimanno A, Perrone T, **Pinto A**. Fotemustine plus etoposide, cytarabine and melphalan [FEAM] as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. *Bone Marrow Transplant*. 2010; 45:1147-53 [I.F. 2.998]
151. Di Francia R, Frigeri F, Berretta M, Cecchin E, Orlando C, **Pinto A**, Pinzani P. Decision Criteria for Rational Selection of Homogeneous Genotyping Platforms for Pharmacogenomics Testing in Clinical Diagnostics. *Clin Chem Lab Med*. 2010; 48:447-59 [I.F. 1.886]
152. Laszlo D, Andreola G, Rigacci L, Fabbri A, Rabascio C, Mancuso P, Pruneri G, Radice D, **Pinto A**, Frigeri F, Calabrese L, Billio A, Bertolini F, Martinelli G. Rituximab And Subcutaneous 2-Chloro-2'-Deoxyadenosine [2-CdA] Combination Treatment For Patients With Waldenstrom's Macroglobulinemia [WM]: Clinical And Biological Results Of A Phase II Multicenter Study. *J Clin Oncol*. 2010;28:2233-8 [I.F. 17.793]
153. Aldinucci D, Gloghini A, **Pinto A**, De Filippi R, Carbone A. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. *J Pathol*. 2010;221:248-63 [IF 6.466]

154. De Luca A, Gallo M, Aldinucci D, Ribatti D, Lamura L, D'Alessio A, De Filippi R, **Pinto A**, Normanno N. The role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells. *J Cell Physiol*. 2011 Aug;226[8]:2131-8. [IF 4.586]
155. Laszlo D, Andreola G, Rigacci L, Fabbri A, Rabascio C, **Pinto A**, Negri M, Martinelli G. Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine as therapy in untreated and relapsed Waldenström's macroglobulinemia. *Clin Lymphoma Myeloma Leuk*. 2011 Feb;11[1]:130-2 [IF 1.988]
156. Corazzelli G, Frigeri F, Arcamone M, Lucania A, Rosariavilla M, Morelli E, Amore A, Capobianco G, Caronna A, Becchimanzi C, Volzone F, Marcacci G, Russo F, De Filippi R, Mastrullo L, **Pinto A**. Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone [R-COMP-14] in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy. *Br J Haematol*. 2011 Sep;154[5]:579-89. [IF 4.942]
157. Corazzelli G, Frigeri F, Arcamone M, Aloj L, Capobianco G, Becchimanzi C, Morelli E, Volzone F, Marcacci G, Russo F, De Filippi R, Lastoria S, **Pinto A**. Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas. *Eur J Haematol*. 2011 Dec;87[6]:547-53. [IF 2.785]
158. Morabito F, De Filippi R, Laurenti L, Zirlik K, Recchia AG, Gentile M, Morelli E, Vigna E, Gigliotti V, Calemma R, Amoroso B, Neri A, Cutrona G, Ferrarini M, Molica S, Del Poeta G, Tripodo C, **Pinto A**. The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia. *Blood*. 2011 Dec 8;118[24]:6353-61. [IF 10.558]
159. De Benedetta G., Bolognini I, D'Ovidio S, **Pinto A**. Cancer and Anorexia Nervosa in the Adolescence: A Family-Based Systemic Intervention. *Int J Family Med*. 2011:769-869
160. Corazzelli G, Russo F, **Pinto A**. ABVD versus BEACOPP for Hodgkin's lymphoma. *N Engl J Med*. 2011 Oct 20; 365[16]:1545 [IF 53.48]
161. **Pinto A**, Corazzelli G, De Filippi R. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. *Cancer*. 2012 Mar 15;118[6]:1738 [IF 5.131]

162. Corazzelli G, Frigeri F, Russo F, Frairia C, Arcamone M, Esposito G, De Chiara A, Morelli E, Capobianco G, Becchimanzi C, Volzone F, Saggese M, Marcacci G, De Filippi R, Vitolo U, **Pinto A**. RD-CODOX-M/TVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma. *Br J Haematol*. 2012 Jan;156[2]:234-44. [IF 4.942]
163. Aldinucci D, Gloghini A, **Pinto A**, Colombatti A, Carbone A. The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment. *Leuk Lymphoma*. 2012 Feb;53[2]:195-201. [IF 2.069]
164. Schwartzberg LS, Jacobs P, Matsouka P, Azevedo W, **Pinto A**. The role of second-generation 5-HT[3] receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies. *Crit Rev Oncol Hematol*. 2012 Jul;83[1]:59-70 [IF 4.689]
165. Arrichiello C, Aloj L, Mormile M, D'Ambrosio L, Frigeri F, Caracò C, Arcamone M, De Martinis F, **Pinto A**, Lastoria S. Feasibility of bremsstrahlung dosimetry for direct dose estimation in patients undergoing treatment with [90]Y-ibritumomab tiuxetan. *Eur J Nucl Med Mol Imaging*. 2012 Jun;39[6]:956-66 [IF 5.036]
166. Scholz CW, **Pinto A**, Linkesch W, Lindén O, Viardot A, Keller U, Hess G, Lastoria S, Lerch K, Frigeri F, Arcamone M, Stroux A, Frericks B, Pott C, Pezzutto A.[90]Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. *J Clin Oncol*. 2013 Jan 20;31[3]:308-13. [IF 18.372]
167. Corazzelli G, Angrilli F, D'Arco A, Ferrara F, Musto P, Guarini A, Cox MC, Stelitano C, Storti S, Iannitto E, Falorio S, Califano C, Amore A, Arcamone M, De Filippi R, **Pinto A**. Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. *Br J Haematol*. 2013 Jan;160 [2]:207-15. [IF 4.941]
168. Vanazzi A, Grana C, Crosta C, Pruneri G, Rizzo S, Radice D, **Pinto A**, Calabrese L, Paganelli G, Martinelli G. Efficacy of 90 Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma. *Hematol Oncol*. 2014 Mar;32[1]:10-5. [IF 2.475]
169. Golay J, Semenzato G, Rambaldi A, Foà R, Gaidano G, Gamba E, Pane F, **Pinto A**, Specchia G, Zaja F, Regazzi M. *MAbs*. 2013 Aug 8;5[6]. [IF 5.275]

170. Vitolo U, Ladetto M, Boccomini C, Baldini L, De Angelis F, Tucci A, Botto B, Chiappella A, Chiarenza A, **Pinto A**, De Renzo A, Zaja F, Castellino C, Bari A, Alvarez De Celis I, Evangelista A, Parvis G, Gamba E, Lobetti-Bodoni C, Ciccone G, Rossi G. Rituximab Maintenance Compared With Observation After Brief First-Line R-FND Chemoimmunotherapy With Rituximab Consolidation in Patients Age Older Than 60 Years With Advanced Follicular Lymphoma: A Phase III Randomized Study by the Fondazione Italiana Linfomi. *J Clin Oncol*. 2013 Sep 20;31[27]:3351-9 [IF 18.372]
171. Montella M, Malvezzi M, Grimaldi M, Nocerino F, Frigeri F, **Pinto A**, Giudice A, Crispo A. Mortality trend for tumor correlated immune system in hyperendemic area of HCV infection in southern Italy: joinpoint analysis. *Hepat Mon*. 2013 Aug 27;13[8]:e12725. [IF 1.245]
172. Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, Chiappella A, Baldini L, Rossi G, Pulsoni A, Di Raimondo F, Rigacci L, **Pinto A**, Galimberti S, Bari A, Rota-Scalabrini D, Ferrari A, Zaja F, Gallamini A, Specchia G, Musto P, Rossi FG, Gamba E, Evangelista A, Vitolo U; Fondazione Italiana Linfomi. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. *Blood*. 2013 Nov 28;122[23]:3759-66. [IF 9.898]
173. Aquino G, Marra L, Cantile M, De Chiara A, Liguori G, Curcio MP, Sabatino R, Pannone G, **Pinto A**, Botti G, Franco R. MYC chromosomal aberration in differential diagnosis between Burkitt and other aggressive lymphomas. *Infect Agent Cancer*. 2013 Sep 30;8[1]:37 [IF 1.716]
174. Aloj L, D'Ambrosio L, Aurilio M, Morisco A, Frigeri F, Caraco' C, Di Gennaro F, Capobianco G, Giovannoni L, Menssen HD, Neri D, **Pinto A**, Lastoria S. Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma. *Eur J Nucl Med Mol Imaging*. 2014 May;41[5]:867-77. [IF 5.114].
175. Russo F, Corazzelli G, Frigeri F, Capobianco G, Aloj L, Volzone F, De Chiara A, Bonelli A, Gatani T, Marcacci G, Donnarumma D, Becchimanzi C, de Lutio E, Ionna F, De Filippi R, Lastoria S, **Pinto A**. Phase II study of dose-dense and dose-intense ABVD [ABVD_{DD-DI}] without consolidation radiotherapy in patients with advanced Hodgkin Lymphoma. *Br J Haematol*. 2014 Jul;166[1]:118-29. [IF 4.942]

176. Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, **Pinto A**, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldles C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, Anderson K, Fermand JP, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C, Facon T; FIRST Trial Team. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. *N Engl J Med*. 2014 Sep 4;371[10]:906-17. [IF 54.42]
177. Zinzani PL, Federico M, Oliva S, **Pinto A**, Rigacci L, Specchia G, Tucci A, Vitolo U. The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma. *Leuk Lymphoma*. 2015 Jan;56[1]:12-25. [IF 2.891]
178. **Pinto A**, Corradini P, Mussetti A, Zinzani PL. Recurrent Hodgkin lymphoma: toward a new definition of candidates for autologous stem cell transplant in the era of positron emission tomography scan and novel agents. *Leuk Lymphoma*. 2015 Jul;56[7]:1969-74. [IF 2.891]
179. Zinzani PL, Pellegrini C, Cantonetti M, Re A, **Pinto A**, Pavone V, Rigacci L, Celli M, Broccoli A, Argnani L, Pulsoni A. Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients. *Oncologist*. 2015 Dec; 20[12]:1413-6. [IF 4.865]
180. Musso M, Messina G, Marcacci G, Crescimanno A, Console G, Donnarumma D, Scalone R, **Pinto A**, Martino M. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study. *Biol Blood Marrow Transplant*. 2015 Nov;21[11]:1932-8. [IF 3.404]
181. **Pinto A**, Corazzelli G. Feasibility and efficacy of dose-dense and dose-intense ABVD for high-risk patients with advanced Hodgkin lymphoma. *Br J Haematol*. 2015 Nov;171[4]:665-8. [IF 4.942]
182. Luminari S, Goldaniga M, Cesaretti M, Orsucci L, Tucci A, Pulsoni A, Salvi F, Arcaini L, Carella AM, Tedeschi A, **Pinto A**, Stelitano C, Baldini L. A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma. *Leuk Lymphoma*. 2016 Apr;57[4]:880-7. [IF 2.891]
183. Musso M, Messina G, Di Renzo N, Di Carlo P, Vitolo U, Scalone R, Marcacci G, Scalzulli PR, Moscato T, Matera R, Crescimanno A, Santarone S, Orciuolo E, Merenda A, Pavone V, Pastore D, Donnarumma D, Carella AM, Ciochetto C, Cascavilla N, Mele A, Lanza F, Di Nicola M, Bonizzoni E, **Pinto A**. Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen. *Br J Haematol*. 2016 Jan;172[1]:111-21. [IF 4.942]

184. Franco R, Scognamiglio G, Valentino E, Vitiello M, Luciano A, Palma G, Arra C, La Mantia E, Panico L, Tenneriello V, **Pinto A**, Frigeri F, Capobianco G, Botti G, Cerchia L, De Chiara A, Fedele M. PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas. *Oncotarget*. 2016 Sep 13;7(37):59158-59172 [IF 5.008]
185. Ascierto PA, Carteni G, Gridelli C, Pignata S, **Pinto A**, Criscitiello C, Buonaguro L, Pepe S, Mabilia R, Montesarchio V, Daniele B, De Placido S. What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO). *Journal for Immunotherapy of Cancer*. 2016; 4:41
186. Taborelli M, Polesel J, Montella M, Libra M, Tedeschi R, Battiston M, Spina M, Di Raimondo F, **Pinto A**, Crispo A, Grimaldi M, Franceschi S, Dal Maso L, Serraino D. Hepatitis B and C viruses and risk of non-Hodgkin lymphoma: a case-control study in Italy. *Infect Agent Cancer*. 2016 Jun 23;11:27 [IF 1.716]
187. Galati D, Corazzelli G, De Filippi R, **Pinto A**. Dendritic cells in hematological malignancies. *Crit Rev Oncol Hematol*. 2016 Dec;108:86-96. [IF 5.039]
188. Pellegrini C, Broccoli A, Pulsoni A, Rigacci L, Patti C, Gini G, Mannina D, Tani M, Rusconi C, Romano A, Vanazzi A, Botto B, Santoro A, Hoaus S, Rigolin GM, Musto P, Mazza P, Molica S, Corradini P, Fama A, Gaudio F, Merli M, Ronconi F, Gritti G, Vallisa D, Tosi P, Liberati AM, **Pinto A**, Pavone V, Gherlinzoni F, Bianchi MP, Volpetti S, Trentin L, Goldaniga MC, Bonfichi M, De Renzo A, Schiavotto C, Spina M, Carella AM, Stefoni V, Argnani L, Zinzani PL. Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma. *Oncotarget*. 2017 May 23;8(53):91703-91710. [IF 5.008]
189. Sabatino R, Aquino G, **Pinto A**, Piris MA, Marra L, Napolitano M, De Chiara A, Franco R. B-cell lymphoblastic lymphoma presenting as solitary temporal mass with amplification of AML1/RUNX1: case report. *Hematol Oncol*. 2017 Sep;35(3):380-384. [IF 3.118]
190. Broccoli A, Pellegrini C, Di Rocco A, Puccini B, Patti C, Gini G, Mannina D, Tani M, Rusconi C, Romano A, Vanazzi A, Botto B, Carlo-Stella C, Hohaus S, Musto P, Mazza P, Molica S, Corradini P, Fama A, Gaudio F, Merli M, Gravetti A, Gritti G, Arcari A, Tosi P, Liberati AM, **Pinto A**, Pavone V, Gherlinzoni F, Naso V, Volpetti S, Trentin L, Goldaniga MC, Bonfichi M, De Renzo A, Schiavotto C, Spina M, Storti S, Carella AM, Stefoni V, Argnani L, Zinzani PL. Italian real life experience with brentuximab vedotin: results of a large observational study on 40 relapsed/refractory systemic anaplastic large cell lymphoma. *Haematologica*. 2017 Nov;102(11):1931-1935. [IF 7.702]

191. Vitolo U, Trněný M, Belada D, Burke JM, Carella AM, Chua N, Abrisqueta P, Demeter J, Flinn I, Hong X, Kim WS, **Pinto A**, Shi YK, Tatsumi Y, Oestergaard MZ, Wenger M, Fingerle-Rowson G, Catalani O, Nielsen T, Martelli M, Sehn LH. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. *J Clin Oncol*. 2017 Nov 1;35(31):3529-3537. [IF 24.008]
192. Brancaccio G, Sorbo MC, Frigeri F, Rizzo V, Cantone M, Genderini F, Fabeni L, **Pinto A**, Perno CF, Ceccherini-Silberstein F, Gaeta GB. Treatment of Acute Hepatitis C With Ledipasvir and Sofosbuvir in Patients With Hematological Malignancies Allows Early Re-start of Chemotherapy. *Clin Gastroenterol Hepatol*. 2018 Jun;16(6):977-978. [IF 7.398]
193. Boriani G, Corradini P, Cuneo A, Falanga A, Foà R, Gaidano G, Ghia PP, Martelli M, Marasca R, Massaia M, Mauro FR, Minotti G, Molica S, Montillo M, **Pinto A**, Tedeschi A, Vitolo U, Zinzani PL. Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. *Hematol Oncol*. 2018 Oct;36(4):624-632. [IF 3.193]
194. Di Francia R, De Monaco A, Saggese M, Iaccarino G, Crisci S, Frigeri F, De Filippi R, Berretta M, **Pinto A**. Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy. *Curr Cancer Drug Targets*. 2018;18(5):499-511. [IF 2.626]
195. Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M, **Pinto A**, Weisel K, Ludwig H, Bahlis NJ, Banos A, Tiab M, Delforge M, Cavenagh JD, Geraldès C, Lee JJ, Chen C, Oriol A, De La Rubia J, White D, Binder D, Lu J, Anderson KC, Moreau P, Attal M, Perrot A, Arnulf B, Qiu L, Roussel M, Boyle E, Manier S, Mohty M, Avet-Loiseau H, Leleu X, Ervin-Haynes A, Chen G, Houck V, Benboubker L, Hulin C. Final analysis of survival outcomes in the randomized phase 3 FIRST trial. *Blood*. 2018 Jan 18;131(3):301-310. [IF 13.164]
196. Zinzani PL, Santoro A, Chiti A, Lastoria S, **Pinto A**, Rigacci L, Barosi G, Pennisi M, Corradini P. Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma. *Leuk Lymphoma*. 2018 Oct 15:1-10. [IF 2.644]
197. Galati D, Zanotta S, Corazzelli G, Bruzzese D, Capobianco G, Morelli E, Arcamone M, De Filippi R, **Pinto A**. Circulating dendritic cells deficiencies as a new biomarker in classical Hodgkin lymphoma. *Br J Haematol*. 2019 Feb;184(4):594-604. [IF 5.128]
198. Leonard JP, Trněný M, Izutsu K, Fowler NH, Hong X, Zhu J, Zhang H, Offner F, Scheliga A, Nowakowski GS, **Pinto A**, Re F, Fogliatto LM, Scheinberg P, Flinn IW, Moreira C, Cabeçadas J, Liu D, Kalambakas S, Fustier P, Wu C, Gribben JG. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. *J Clin Oncol*. 2019 May 10;37(14):1188-1199 [IF 26.303]

199. Crisci S, Di Francia R, Mele S, Vitale P, Ronga G, De Filippi R, Berretta M, Rossi P, **Pinto A**. Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas. *Front Oncol*. 2019 Jun 4;9:443. [IF 4.137]
200. Bellocchi MC, Aragri M, Carioti L, Fabeni L, Pipitone RM, Brancaccio G, Sorbo MC, Barbaliscia S, Di Maio VC, Bronte F, Grimaudo S, Mazzucco W, Frigeri F, Cantone M, **Pinto A**, Perno CF, Craxì A, Gaeta GB, Di Marco V, Ceccherini-Silberstein F. NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients. *Cells*. 2019 Jul 2;8(7). pii: E666. [IF 5.656]
201. Broccoli A, Argnani L, Botto B, Corradini P, **Pinto A**, Re A, Vitolo U, Fanti S, Stefoni V, Zinzani PL. First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi. *Blood Cancer J*. 2019 Dec 11;9(12):100. [IF 8.023]
202. Stefoni V, Marangon M, Re A, Lleshi A, Bonfichi M, **Pinto A**, Bianchetti N, Pellegrini C, Argnani L, Zinzani PL. Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase 2 study of FIL ONLUS. *Haematologica*. 2020 Feb 13. pii: haematol.2019.243170. doi: 10.3324/haematol.2019.243170. [Epub ahead of print] [IF 7.570]
203. Carpio C, Bouabdallah R, Ysebaert L, Sancho JM, Salles GA, Cordoba R, **Pinto A**, Gharibo M, Rasco D, Panizo C, Lopez-Martin JA, Santoro A, Salar A, Damian S, Martin Garcia-Sancho A, Verhoef G, Van Den Neste EW, Wang M, Couto S, Carrancio S, Weng A, Wang X, Schmitz F, Wei X, Hege KM, Trotter MWB, Risueno A, Buchholz T, Hagner PR, Gandhi AK, Pourdehnad M, Ribrag V. Avadomide monotherapy in relapsed/refractory DLBCL: Safety, efficacy, and a predictive gene classifier. *Blood*. 2020 Mar 26;135(13):996-1007. [IF 16.601]
204. Capone M, Fratangelo F, Giannarelli D, Sorrentino C, Turiello R, Zanotta S, Galati D, Madonna G, Tuffanelli M, Scarpato L, Grimaldi AM, Esposito A, Azzaro R, **Pinto A**, Cavalcanti E, Pinto A, Morello S, Ascierto PA. Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients. *J Transl Med*. 2020 Mar 11;18(1):121 [IF 4.098]
205. Galdiero MR, Morelli E, Triggianese P, Carucci L, Punziano A, **Pinto A**, Genovese A, de Paulis A, Spadaro G. First Report of De Novo Nivolumab-Induced Oligoarthritis in a Young Man With Relapsing Classic Hodgkin Lymphoma. *JCR: Journal of Clinical Rheumatology*: June 6, 2020 - Volume Publish Ahead of Print - Issue - doi: 10.1097/RHU.0000000000001459 [IF 1.897]

206. Di Francia R, Crisci S, Muto T, Giancola C, Petriccone L, Catapano O, Cummaro A, **Pinto A**, Frigeri F. Optimization of a Low-Cost, Sensitive PNA Clamping PCR Method for JAK2 V617F Variant Detection. *J Appl Lab Med*. 2020 Jul 1;5(4):643-655.
207. Crisci S, Pota E, Iaccarino G, Postiglione I, Meo C, Mele S, De Filippi R, **Pinto A**. Childhood Therapy-Related Acute Myeloid Leukemia with t(16;21)(q24;q22)/RUNX1-CBFA2T3 After a Primitive Neuroectodermal Tumor of the Chest Wall. *Clin Lymphoma Myeloma Leuk*. 2020 May 29:S2152-2650(20)30266-4. doi: 10.1016/j.clml.2020.05.020. Epub ahead of print. PMID: 32651109. [IF 2.274]
208. Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, Angelucci E, Krampera M, Cairoli R, Della Porta MG, Fracchiolla N, Ladetto M, Gambacorti Passerini C, Salvini M, Marchetti M, Lemoli R, Molteni A, Busca A, Cuneo A, Romano A, Giuliani N, Galimberti S, Corso A, Morotti A, Falini B, Billio A, Gherlinzoni F, Visani G, Tisi MC, Tafuri A, Tosi P, Lanza F, Massaia M, Turrini M, Ferrara F, Gurrieri C, Vallisa D, Martelli M, Derenzini E, Guarini A, Conconi A, Cuccaro A, Cudillo L, Russo D, Ciambelli F, Scattolin AM, Luppi M, Selleri C, Ortu La Barbera E, Ferrandina C, Di Renzo N, Olivieri A, Bocchia M, Gentile M, Marchesi F, Musto P, Federici AB, Candoni A, Venditti A, Fava C, **Pinto A**, Galieni P, Rigacci L, Armiento D, Pane F, Oberti M, Zappasodi P, Visco C, Franchi M, Grossi PA, Bertù L, Corrao G, Pagano L, Corradini P. ITA-HEMA-COV Investigators. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. *Lancet Haematol*. 2020 Aug 13:S2352-3026 (20) 30251-9. doi:10.1016/S2352-3026(20)30251-9. Epub ahead of print. PMID:32798473. [IF 10.406]
209. Armand P, Janssens AM, Gritti G, Radford J, Timmerman JM, **Pinto A**, Mercadal Vilchez S, Johnson PWM, Cunningham D, Leonard JP, Rodig SJ, Martín-Regueira P, Sumbul A, Samakoglu S, Tang H, Ansell SM. Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. *Blood*. 2020 Aug 31:blood.2019004753. doi: 10.1182/blood.2019004753. Epub ahead of print. PMID: 32870269. [IF 16.601]
210. Zinzani PL, Bregni M, Spione M, Mitterer M, Musuraca G, Bugli A, Piazza F, **Pinto A**. Effectiveness and Safety of Pixantrone for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Every-Day Clinical Practice: The Italian Cohort of the PIXA Registry. *Acta Haematol*. 2020 Oct 9:1-5. doi: 10.1159/000509923. Epub ahead of print. PMID: 33040061. [IF 1.196]

211. Galati D, Zanotta S, Bocchino M, De Filippi R, **Pinto A**. The subtle interplay between gamma delta T lymphocytes and dendritic cells: is there a role for a therapeutic cancer vaccine in the era of combinatorial strategies? *Cancer Immunol Immunother*. 2021 Jul;70(7):1797-1809. doi: 10.1007/s00262-020-02805-3. [IF 5.442]
212. Kostakoglu L, Martelli M, Sehn LH, Belada D, Carella AM, Chua N, Gonzalez-Barca E, Hong X, **Pinto A**, Shi Y, Tatsumi Y, Knapp A, Mattiello F, Nielsen T, Sahin D, Sellam G, Oestergaard MZ, Vitolo U, Trněný M. End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA. *Blood Adv*. 2021 Mar 9;5(5):1283-1290. doi: 10.1182/bloodadvances.2020002690. PMID: 33651099; PMCID: PMC7948296. [IF 4.910]
213. Di Francia R, Crisci S, De Monaco A, Cafiero C, Re A, Iaccarino G, De Filippi R, Frigeri F, Corazzelli G, Micera A, **Pinto A**. Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers. *Cancers (Basel)*. 2021 Feb 25;13(5):966. doi: 10.3390/cancers13050966. PMID: 33669053; PMCID: PMC7956511. [IF 6.126]
214. Marcacci G, Fiorentino G, Volzone F, Falcone U, Parrella R, Donnarumma D, D'Ovidio S, Annunziata A, Micallo G, Portella G, De Chiara A, De Filippi R, Crisci S, **Pinto A**. Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab. *Infect Agent Cancer*. 2021 Jun 2;16(1):38. doi: 10.1186/s13027-021-00376-1. PMID: 34078415; PMCID: PMC8170447. [IF 2.965]
215. Passamonti F, Romano A, Salvini M, Merli F, Porta MGD, Bruna R, Coviello E, Romano I, Cairoli R, Lemoli R, Farina F, Venditti A, Busca A, Ladetto M, Massaia M, **Pinto A**, Arcaini L, Tafuri A, Marchesi F, Fracchiolla N, Bocchia M, Armiento D, Candoni A, Krampera M, Luppi M, Cardinali V, Galimberti S, Cattaneo C, La Barbera EO, Mina R, Lanza F, Visani G, Musto P, Petrucci L, Zaja F, Grossi PA, Bertù L, Pagano L, Corradini P; ITA-HEMA-COV Investigators*. COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. *Br J Haematol*. 2021 Nov;195(3):371-377. doi: 10.1111/bjh.17704. Epub 2021 Jul 16. PMID: 34272724; PMCID: PMC8444788. [IF 6.998]
216. Kostakoglu L, Mattiello F, Martelli M, Sehn LH, Belada D, Ghiggi C, Chua N, González-Barca E, Hong X, **Pinto A**, Shi Y, Tatsumi Y, Bolen C, Knapp A, Sellam G, Nielsen T, Sahin D, Vitolo U, Trněný M. Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study. *Haematologica*. 2021 Aug 19. doi: 10.3324/haematol.2021.278663. Epub ahead of print. PMID: 34407602. [IF 9.941]


217. Visco C, Marcheselli L, Mina R, Sassone M, Guidetti A, Penna D, Cattaneo C, Bonuomo V, Busca A, Ferreri AJM, Bruna R, Petrucci L, Cairoli R, Salvini M, Bertù L, Ladetto M, Pileri S, **Pinto A**, Ramadan S, Marchesi F, Cavo M, Arcaini L, Coviello E, Romano A, Musto P, Massaia M, Fracchiolla NS, Marchetti M, Scattolin A, Tisi MC, Cuneo A, Della Porta MG, Trentin L, Turrini M, Gherlinzoni F, Tafuri A, Galimberti S, Bocchia M, Cardinali V, Cilloni D, Corso A, Armiento D, Rigacci L, Ortu La Barbera E, Gambacorti-Passerini CB, Visani G, Vallisa D, Venditti A, Selleri C, Conconi A, Tosi P, Lanza F, Candoni A, Krampera M, Corradini P, Passamonti F, Merli F. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. *Blood Adv.* 2021 Oct 13;bloodadvances.2021005691. doi: 10.1182/bloodadvances.2021005691. Epub ahead of print. PMID: 34644385; PMCID: PMC8516438. [IF 6.799]
218. Luminari S, Manni M, Galimberti S, Versari A, Tucci A, Boccomini C, Farina L, Olivieri J, Marcheselli L, Guerra L, Ferrero S, Arcaini L, Cavallo F, Kovalchuk S, Skrypets T, Del Giudice I, Chauvie S, Patti C, Stelitano C, Ricci F, **Pinto A**, Margiotta Casaluci G, Zilioli VR, Merli A, Ladetto M, Bolis S, Pavone V, Chiarenza A, Arcari A, Anastasia A, Dondi A, Mannina D, Federico M; Fondazione Italiana Linfomi. Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. *J Clin Oncol.* 2021 Oct 28;JCO2101234. doi: 10.1200/JCO.21.01234. Epub ahead of print. PMID: 34709880. [IF 44.544]
219. De Filippi R, Morabito F, Santoro A, Tripepi G, D'Alò F, Rigacci L, Ricci F, Morelli E, Zinzani PL, **Pinto A**. Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab. *J Transl Med.* 2021 Dec 1;19(1):489. doi: 10.1186/s12967-021-03134-4. PMID: 34852840; PMCID: PMC8638339. [IF 8.440]
220. Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, **Pinto A**, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers CR, Salles G. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. *N Engl J Med.* 2021 Dec 14. doi: 10.1056/NEJMoa2115304. Epub ahead of print. PMID: 34904799. [IF 91.245]

221. Rieger K, De Filippi R, Lindén O, Viardot A, Hess G, Lerch K, Neumeister P, Stroux A, Peuker CA, Pezzutto A, **Pinto A**, Keller U, Scholz CW. 90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years. *Ann Hematol.* 2022 Apr;101(4):781-788. doi: 10.1007/s00277-022-04781-3. Epub 2022 Feb 12. PMID: 35150296; PMCID: PMC8913448. [IF 3.673]
222. Calò F, Onorato L, Pisaturo M, **Pinto A**, Alessio L, Monari C, Minichini C, Arcamone M, Fraia AD, Atripaldi L, Tiberio C, Coppola N. Fatal Outcome of COVID-19 Relapse in a Fully Vaccinated Patient with Non-Hodgkin Lymphoma Receiving Maintenance Therapy with the Anti-CD20 Monoclonal Antibody Obinutuzumab: A Case Report. *Vaccines.* 2022; 10(7):1021. doi.org/10.3390/vaccines10071021 [IF 4.961]
223. Zappasodi P, Cattaneo C, Ferretti V, Mina R, María Ferreri AJ, Merli F, Oberti M, Krampera M, Romano A, Zerbi C, Ferrari J, Cavo M, Salvini M, Bertù L, Fracchiolla N, Marchesi F, Massaia M, Marasco V, Cairoli R, Scattolin AM, Vannucchi AM, Gambacorti-Passerini C, Musto P, Gherlinzoni F, Cuneo A, **Pinto A**, Trentin L, Bocchia M, Galimberti S, Coviello E, Tisi MC, Morotti A, Falini B, Turrini M, Tafuri A, Billio A, Gentile M, Lemoli R, Venditti A, Porta MG, Lanza F, Rigacci L, Tosi P, Mohamed S, Corso A, Luppi M, Giuliani N, Busca A, Pagano L, Bruno R, Grossi PA, Corradini P, Passamonti F, Arcaini L; ITA-HEMA-COV Investigators. Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies a report from the ITA-HEMA-COV. *Hematol Oncol.* 2022 Jul 19. doi: 10.1002/hon.3048. Epub ahead of print. PMID: 35854643 [IF 4.850]
224. Marcacci G, Coppola N, Madonna E, Becchimanzi C, De Pascalis S, D'Ovidio S, Crisci S, Maiolino P, De Filippi R, **Pinto A**. Post-exposure prophylaxis with sotrovimab for Omicron (B.1.1.529) SARS-CoV-2 variant during the aplastic phase of autologous stem cell transplantation. *Infect Agent Cancer.* 2022 Aug 3;17(1):41. doi: 10.1186/s13027-022-00454-y. PMID: 35922822. [IF3.698]
225. De Filippi R, Marcacci G, Derenzini E, Musso M, Donnarumma D, Morelli E, Patti C, Maraglino AME, Scalone R, Simeone L, Becchimanzi C, Mele S, Crisci S, Morabito F, **Pinto A**. Anti-PD1 Consolidation in Patients with Hodgkin Lymphoma at High Risk of Relapse after Autologous Stem Cell Transplantation: A Multicenter Real-Life Study. *Cancers (Basel).* 2022 Nov 27;14(23):5846. doi: 10.3390/cancers14235846. PMID: 36497328; PMCID: PMC9739754. [IF6.575]

226. Chiappella A, Dodero A, Evangelista A, Re A, Orsucci L, Usai SV, Castellino C, Stefoni V, **Pinto A**, Zanni M, Ciancia R, Ghiggi C, Rossi FG, Arcari A, Ilariucci F, Zilioli VR, Flenghi L, Celli M, Volpetti S, Benedetti F, Ballerini F, Musuraca G, Bruna R, Patti C, Leonardi F, Arcaini L, Magagnoli M, Cavallo F, Bermema A, Tucci A, Boccomini C, Ciccone G, Carniti C, Pileri SA, Corradini P. Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study. *Leukemia*. 2023;37(2):433-440. doi: 10.1038/s41375-022-01780-1. Epub 2023 Jan 18. PMID: 36653509; PMCID: PMC9898022. [IF12.883]
227. Moreno, V., Vieito, M., Sepulveda, J. M., Galvao, V., Hernández-Guerrero, T., Doger, B., Saavedra, O., Carlo-Stella, C., Michot, J. M., Italiano, A., Magagnoli, M., Carpio, C., **Pinto, A.**, Sarmiento, R., Amoroso, B., Aronchik, I., Filvaroff, E., Hanna, B., Wei, X., Nikolova, Z., ... Braña, I. (2023). BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas. *Nature communications*, 2023; 14(1), 1359. <https://doi.org/10.1038/s41467-023-36976-1> [IF 16.6]
228. Gotti, M., Sciarra, R., Pulsoni, A., Merli, F., Luminari, S., Zerbi, C., Trentin, L., Re, A., Rusconi, C., Viviani, S., Rossi, A., Cocito, F., Botto, B., Meli, E., **Pinto, A.**, Dogliotti, I., Gini, G., Puccini, B., Ricci, F., Nassi, L., ... Arcaini, L. (2023). Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. *Hemasphere*. 2023;7(4):e837. <https://doi.org/10.1097/HS9.0000000000000837> [IF 8.3]
229. Galati D, Zanotta S, Capone M, Madonna G, Mallardo D, Romanelli M, Simeone E, Festino L, Sparano F, Azzaro R, De Filippi R, **Pinto A**, Paulos CM, Ascierto PA. Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients. *J Transl Med*. 2023;21(1):318. doi: 10.1186/s12967-023-04184-6. PMID: 37170241; PMCID: PMC10176780. [IF 6.1]
230. Ladetto M, Tavarozzi R, Zanni M, Evangelista A, Ferrero S, Tucci A, Botto B, Bolis S, Volpetti S, Zilioli VR, Puccini B, Arcari A, Pavone V, Gaidano G, Corradini P, Tani M, Cavallo F, Milone G, Ghiggi C, **Pinto A**, Pastore D, Ferreri AJM, Latte G, Patti C, Re F, Benedetti F, Luminari S, Pennese E, Bossi E, Boccomini C, Anastasia A, Bottelli C, Ciccone G, Vitolo U. Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial. *Ann Oncol*. 2024;35(1):118-129. doi: 10.1016/j.annonc.2023.10.095. Epub 2023 Nov 3. PMID: 37922989. [IF 56.7]

231. **Pinto A**, Ladetto M, Martelli M, Visco C, Zaja F, Guardalben E, Zinzani PL. Unmet needs in relapsed/refractory mantle cell lymphoma after failure of covalent Bruton's tyrosine kinase inhibitors: An Italian scenario. *Hematol Oncol*. 2024;42(1):e3246. doi: 10.1002/hon.3246. PMID: 38287533. [IF 3.3]
232. Zanotta S, Galati D, De Filippi R, **Pinto A**. Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123. *Int J Mol Sci*. 2024; 25(3):1454. doi: 10.3390/ijms25031454. PMID: 38338733; PMCID: PMC10855071. [IF 4.9]
233. Fardella E, Zanirato G, Magni M, Caldarelli N, Chiappella A, Dodero A, Ljevar S, Orsucci L, Re A, Usai SV, Stefoni V, Castellino C, Rossi FG, **Pinto A**, Carniti C, Corradini P. Prognostic impact of pretreatment cell-free DNA concentration in newly diagnosed peripheral T-cell lymphomas. *Br J Haematol*. 2024;204(5):1752-1756. doi: 10.1111/bjh.19280. Epub 2024 Jan 4. PMID: 38176400. [IF 5.1]

Naples, June 27, 2024



Antonio Pinto, MD